The FDA gave GlaxoSmithKline a lesson in geometry last week when it sent the company a warning letter over its "misleading" claims for Avodart, a prostate reduction drug. FDA's main objection was the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback